格隆汇APP·2026-03-31 09:58Core Viewpoint - 2025 marks a significant year for China's innovative pharmaceuticals, with the Hengsheng Hong Kong Stock Connect Innovative Drug Select Index experiencing a year-to-date increase of over 125%, indicating a record high in industry prosperity. Heng Rui Pharmaceutical achieved historical revenue of 31.6 billion yuan and a net profit of 7.7 billion yuan, with innovative drug sales accounting for 58% of total revenue, expected to grow over 30% year-on-year in 2026 [2][11]. Group 1: Company Performance - Heng Rui Pharmaceutical's revenue and net profit reached 31.6 billion yuan and 7.7 billion yuan respectively, both setting historical records [2]. - The proportion of innovative drug sales surged to 58%, with a projected year-on-year growth rate exceeding 30% for 2026 [2][11]. - The company successfully completed an A+H listing, raising a net amount of 11.374 billion HKD, marking the largest IPO in the Hong Kong pharmaceutical sector in the past five years [9]. Group 2: Research and Development - Heng Rui's R&D investment reached 8.724 billion yuan in 2025, accounting for 27.58% of its revenue, translating to nearly 24 million yuan spent on R&D daily [5]. - The company ranked second globally in the scale of self-developed pipelines, with a growth rate among the top three worldwide [5]. - In 2025, Heng Rui obtained approvals for 7 class 1 innovative drugs and 1 class 2 new drug, significantly increasing the number of approved innovative drugs to 24 class 1 and 5 class 2 [8]. Group 3: Market Dynamics and Growth Drivers - The adjustment of the national medical insurance catalog at the end of 2025 is expected to drive growth in 2026, with 20 products/indications entering the new catalog, including 10 products newly covered by insurance [12]. - A significant increase in clinical data readouts is anticipated in 2026, with approximately 25 new molecular entities (NME) expected to report phase III clinical data [12]. - The company has established strategic alliances, including a notable partnership with GSK, which involves the development of up to 12 innovative drugs, with potential total payments reaching approximately 12 billion USD [15]. Group 4: Global Expansion and Strategic Positioning - Heng Rui is building a global network with 15 R&D centers established across Asia, Europe, and Australia, and has initiated overseas clinical trials [20]. - Since 2023, the company has completed 12 overseas business expansion transactions, with a potential total transaction value exceeding 27 billion USD, partnering with top global pharmaceutical companies [22]. - The strategic value of Heng Rui has transcended the company itself, aligning with China's biopharmaceutical industry growth, with an expected 53 innovative products and indications to be approved between 2026 and 2028 [23][24].